| INTRODUCTION
Proton pump inhibitors (PPIs) are among the world's most frequently prescribed medications, for which estimated sales are in excess of USD$10 billion worldwide. [1] [2] [3] However, 30%-60% of prescriptions may be inappropriate, 4, 5 and although generally well tolerated, serious PPI adverse events include increased risk of community-and hospital-acquired pneumonia, 6 Clostridium difficile enterocolitis, 7 interstitial nephritis, 8 bone fracture 9 and hypomagnesemia. 10 Evidence supports the use of PPIs for gastro-oesophageal reflux disease, 11 peptic ulcer disease, 12 and for mitigating the risk of gastrointestinal (GI) bleeding associated with anti-platelet therapy. 13, 14 As PPIs significantly reduce the risk of GI bleeding associated with anti-platelet therapy, PPIs are often administered in combination with clopidogrel. 13 Clopidogrel is a first-line anti-platelet prodrug indicated for the secondary prevention of atherothrombotic cardiovascular disease. 14, 15 Pharmacokinetic studies have postulated an interaction between PPIs and clopidogrel, arising from metabolism by the same hepatic isoenzyme (CYP2C19). [16] [17] [18] Inhibition of CYP2C19 by PPIs may reduce the bioavailability of the active metabolites of clopidogrel, and attenuate clopidogrel's cardiovascular benefits. [16] [17] [18] As a result, the United States Food and Drug Administration (FDA) has warned against using clopidogrel in combination with the PPIs omeprazole and esomeprazole. 19 Observational studies and randomised controlled trials have yielded conflicting results as to whether the proposed pharmacokinetic interaction between PPIs and clopidogrel manifests as an increased clinical risk of adverse cardiovascular events. [20] [21] [22] [23] [24] Furthermore, it has been suggested that the observed risk of PPI use with anti-platelet therapy may be partly due to an increase in cardiovascular risk conferred by PPIs directly. 25, 26 To help address this theory, a systematic review and meta-analysis was conducted to explore the association between cardiovascular risk and PPIs independent of concomitant clopidogrel therapy.
| ME TH ODS
A systematic review and meta-analysis was conducted in accordance with the checklist outlined by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement (Supporting Information Data S1). 27 The systematic review protocol is registered on PROSPERO: International prospective register of systematic reviews (ID number CRD42016042187). 28 
| Search strategy
The electronic databases of MEDLINE (via Ovid), EMBASE, Cochrane
Central Register of Controlled Trials (CENTRAL), Scopus, Web of Science, and ClinicalTrials.gov were systematically searched from inception to October 2017. Search strings included broad medical subject headings and controlled search terms relating to the outcome of adverse cardiovascular events in combination with the prescription, dispensation or use of PPIs as an intervention. The electronic search string was adapted for each database and database-specific filtres were used. The search strategy conducted for MEDLINE (via Ovid) is included in Supporting Information Data S2.
Reference lists of relevant systematic reviews, letters and other nonprimary data sources captured by the search strategy were also screened to allow for identification of relevant studies that may have otherwise been missed.
| Inclusion and exclusion criteria
Original, peer-reviewed, research studies using human subjects and published in English were eligible for inclusion. Studies were included if primary data indicated exposure to PPIs, along with new onset or worsening cardiovascular disease of any subtype. Randomised controlled trials comparing PPI to active interventions (ie, anything other than placebo) were excluded. Studies involving participants aged under 18 years and studies including PPI concomitant therapy without assessing PPI as an independent risk factor (most commonly, in combination with anti-platelet therapy) were excluded. Case studies were also excluded. Conference abstracts and studies where full articles could not be retrieved were not initially excluded from the search strategy but later excluded from the meta-analysis. Qualitative data from these studies in included in Supporting Information Data S5.
| Study selection
Identified studies were imported into EndNote ® and duplicates deleted. Two investigators (RB and RK) independently screened all titles and abstracts returned by the search strategy. Two investigators (RB and RK) independently assessed all full text copies of potentially relevant studies returned by title and abstract screening. Both title and abstract screen and full text screen were performed with both authors viewing every abstract or full text returned to minimise human error. A third investigator (DL) resolved any discordance in assessments.
| Data collection
Two investigators (RB and RK) independently used a standardised, pre-piloted data extraction form to retrieve relevant quantitative data from included studies. This data form was electronically generated using Google Sheets. The data form extracted study characteristics (author, study design, country), type of PPI and ascertainment of exposure, type of adverse cardiovascular event and ascertainment of outcome, measures of association, follow-up, and adjustment for confounders. The data extraction form was based on the minimum requirements recommended in the Cochrane Handbook for Systematic Reviews. 29 BATCHELOR ET AL.
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| Risk of bias assessment
Two investigators (RB and RK) assessed risk of bias, and a third investigator (IH) resolved discrepancies by consensus. The Newcastle-Ottawa Scale was used to assess the methodological quality of observational studies in terms of validating participant selection, population comparability, and outcome/exposure assessment. 30 The
Cochrane Tool for Assessing Risk of Bias was used to assess the methodological quality of randomised controlled trials. 31 Although abstracts were encapsulated in the initial search strategy, abstracts were excluded from meta-analysis as risk of bias could not be accurately assessed using data presented.
| Data synthesis and analysis
Measures of association, including odds ratios (ORs), hazard ratios 
| RESULTS

| Search results
The systematic search strategy identified 5285 unique articles, of which 89 were eligible for full text screening. In total, 22 studies met the inclusion criteria (including three abstracts which were excluded from meta-analysis). [24] [25] [26] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] The most common reasons for study exclusion were noncardiovascular outcomes (encapsulated by the broad search strategy), and the use of concomitant anti-platelet therapy. The screening process and further reasons for exclusion are documented using the PRISMA flow diagram presented in Figure 1 . 27 Data from 16 [24] [25] [26] [36] [37] [38] [39] [40] 42, [44] [45] [46] [47] [48] 50, 52 of the 22 studies were included in the meta-analyses, which were undertaken separately for randomised controlled trials and observational studies.
Three abstracts encapsulated by the search strategy were excluded from meta-analyses as risk of bias could not be accurately assessed. 35, 41, 49 Three full text studies were excluded as they did not have comparable methodology or quantitative data that could be accurately pooled. 43, 51, 53 These three excluded studies comprised a self-matched case series, 43 a case-crossover study, 51 and a cohort study. Specific PPIs examined across all studies included omeprazole (n = 8 studies), esomeprazole (n = 8), lansoprazole (n = 8), pantoprazole (n = 7), rabeprazole (n = 6) and dexlansoprazole (n = 4).
The definition of major adverse cardiac event varied. Combinations of acute coronary syndrome, ischaemic stroke, cardiovascular hospitalisation, stent thrombosis and cardiovascular death were used to define the broad outcome. Eight studies reported data on fatal and nonfatal acute myocardial infarction (AMI) specifically. 25, 26, 37, 39, 40, 42, 47, 52 The same seven studies that used prescription or pharmacy dispensing record databases to determine exposure used diagnostic codes to identify cases of major adverse cardiovascular events. The randomised controlled trials relied on investigator assessment and spontaneous reporting to ascertain adverse events.
This process was not formally adjudicated.
The randomised controlled trials examined PPI use over a duration ranging from four weeks (n = 4) to 26 weeks (n = 4 Overall, randomised controlled trials were assessed as being of overall low risk of bias as per the Cochrane Tool for Assessing Risk of Bias. 31 Dunn et al's post hoc analysis was regarded as high risk in terms of random sequence generation and blinding given that treatments were not randomised. This study was otherwise judged as low risk across the other domains. 38 All eight randomised trials were of low or unclear risk in random sequence generation and concealment of allocation, and all presented satisfactory blinding methods.
One randomised study demonstrated a higher rate of discontinuation in the placebo group and was thus judged high risk of incomplete outcome data. 42 Six randomised trials had registered a protocol with a National Clinical Trial identifier and were identified as being of low risk in selective reporting. [38] [39] [40] 42, 44, 45 Generally, observational studies were conducted appropriately and included clear descriptions of population selection, exposure and Excluded title/abstracts (n = 5196) Reasons for exclusion included: non-primary data, non-English, non-cardiovascular outcome, concomitant antiplatelet therapy, non-PPI therapy (e.g. use of H2-receptor antagonist).
Excluded full text studies (n = 67)
Non-cardiovascular outcome (n = 38) Concomitant therapy (n = 26) No non-PPI control group (n = 1) Overlapping study population (n = 1) Duplicate abstract of published study (n = 1) 
| Meta-analysis of risk of major adverse cardiovascular events with PPI monotherapy
The meta-analysis of eight randomised controlled trials included 2554 patients who received PPI and 1570 who received placebo.
There was little statistical heterogeneity across the studies, and random-effect modelling identified no increase in risk across these stud- Data adjusted for statistical imbalances were included preferentially over crude measures of association with the use of generic inverse variance modelling. No unadjusted effect estimates were used in the meta-analysis. Meta-analysis generated with random-effect modelling generated an overall risk ratio for major adverse cardiovascular events with PPI use of 1.25 (95% CI 1.11-1.42, P < 0.001). However, an I 2 statistic of 81% indicated substantial heterogeneity across observational studies (Figure 3 ).
| Sensitivity analyses
A sensitivity analysis conducted on the meta-analysis of randomised controlled trials demonstrated that no single study influenced the result significantly. Analyses stratified by duration of exposure to PPIs found point estimates on either side of the null, but neither result was statistically significant. Among the four studies which included only four weeks of exposure to PPIs, the RR was 0.66 (95% CI 0.20-2.24, P = 0.62, I 2 0%), 39, 40, 45, 47 while among the four studies in which duration of exposure to PPIs was 26 weeks, the RR was 1.44 (95% CI 0.30-6.98, P = 0.65, I 2 = 0%). 36, 42, 44, 50 Within the pool of data from observational studies, the association between PPI therapy and major adverse cardiovascular outcomes was accentuated, and heterogeneity significantly reduced, when four studies measuring cardiovascular outcomes at a one-year endpoint were pooled (overall risk ratio 1.35; 95% CI 1.18-1.53, P = 0.19; I 2 = 38%). 37, 38, 46, 48 Because the overall meta-analysis pooled studies reporting different measures of association, sensitivity analysis pooling studies reporting HR only was also conducted (HR 1.37; 95% CI 1.24-1.52, P = 0.01, I 2 = 20%). Figure 4 ).
Four observational studies described the association between PPI therapy and AMI. 25, 26, 37, 52 Pooled results from these studies noted a statistically significant increased risk of AMI with PPI therapy, but again, the studies were heterogenous (RR 1.21; 95% CI 1.09-1.34, P = 0.08, I 2 = 56%, Figure 5 ).
| Publication bias
A funnel plot of randomised controlled trials was generated to assess publication bias (Supporting Information Data S5). In the setting of significant heterogeneity (I 2 statistic >50%), asymmetry testing for publication bias by means of funnel plot was not conducted for the observational studies. 55 In lieu of this, efforts were made to limit publication bias by including abstracts presenting eligible data for discussion within this systematic review, despite exclusion from meta-analysis.
| Studies not included in meta-analysis
Six of the 14 studies included in the systematic review were not suitable for meta-analysis. Three of these studies were available only as abstracts. 35, 41, 49 Juurlink et al's 43 self-matched case series identified 5550 hospital admissions for AMI within 12 weeks of commencing PPI therapy.
The risk of AMI within the "risk interval" (weeks 0-4) against the "control interval" (weeks 8-12) increased (OR 1.8; 95% CI 1.7-1.9),
suggesting an increased short-term risk of AMI with PPI therapy. 43 However, similarly raised ORs were noted for medications not known to be cardiotoxic, suggestive of significant confounding and no causal relationship. 43 Tau 
| Potential pathogenic mechanisms by which
PPIs increase cardiovascular risk
PPIs may attenuate clopidogrel's anti-platelet effects by inhibiting CYP2C19, which metabolises clopidogrel to its active metabolites. [16] [17] [18] [19] However, PPIs may exert adverse cardiovascular effects beyond this pharmacokinetic drug-drug interaction, as evidenced by: the association between cardiovascular risk and PPIs that are not known to inhibit CYP2C19 (eg, pantoprazole) among patients taking concomitant clopidogrel 58 and the increased cardiovascular risk associated with PPIs among patients taking anti-platelet agents that are not dependent on CYP2C19 (eg, aspirin 59 and ticagrelor). Asymmetric dimethylarginine (ADMA) is an endogenous competitive inhibitor of NO synthase. 62 Increased plasma ADMA levels are therefore associated with an increased risk of adverse cardiovascular events. 63 Ghebremariam et al 64 suggested that PPIs directly inhibit the activity of dimethylargininase (DDAH), an enzyme which metabolises ADMA, thereby increasing plasma ADMA levels and impairing vascular NO synthesis. The same authors conducted a subsequent cross-over study examining vascular function (using the EndoPAT device) 65 and plasma ADMA levels over a 4-week period of PPI exposure. 66 Although PPI use was associated with an increase A final suggested mechanism involves lowering and severe depletion of plasma magnesium, which is crucial to cardiac electrophysiology, leading to cardiac arrhythmias and congestive heart failure. 71, 72 Electrolyte imbalances such as hypomagnesaemia have been observed to occur with PPI use. The observational studies included in the present meta-analysis adjusted for age, sex, diabetes, hypertension and hyperlipidaemia, 73, 74 but not obesity, diet, alcohol consumption, physical exercise, insulin resistance and family history of cardiovascular disease. [75] [76] [77] Confounding by indication was also a possibility. Gastrooesophageal reflux disease has been associated with an increased risk of adverse cardiovascular events in large observational studies, 78, 79 and only two of the eight studies included in the meta-analysis of non-randomised data adjusted for the presence of gastrooesophageal reflux disease. 25, 46 In addition, residual confounding by unknown factors was also a possibility. PPIs. The lack of evidence of an association between histamine-2 receptor antagonists and cardiovascular risk also suggests that protopathic bias in unlikely to be present, which arises when the intervention is in response to a symptom of the undiagnosed outcome.
This is relevant as dyspepsia can mimic the prodromal symptoms of ischaemic myocardial pain and has been proposed to lead to misidentification of acute coronary syndrome as gastro-oesophageal reflux disease. 
| Limitations
A methodological limitation of the present systematic review and meta-analysis stemmed from heterogeneity in the nonrandomised studies. Furthermore, studies reporting odds ratios did not contain data necessary to generate time-dependent measures, and thus were pooled with hazard ratios in meta-analysis without conversion. However, given that major adverse cardiovascular events were rare in the component studies, this was unlikely to have impacted the results of meta-analysis significantly. In addition, effect size was not dependent on how the measure of effect was expressed. The pooling of different measures of effect size has also been undertaken in other large meta-analysis under similar circumstances. 6, 23 Nonetheless, to address the issue, sensitivity analysis of studies reporting BATCHELOR ET AL.
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None of the eight randomised controlled trials included in the present review strictly excluded clopidogrel users. However, these trials minimised participation by people with known cardiovascular disease or who were using clopidogrel. At a minimum, all trials sought to differentiate patients with myocardial chest pain from reflux-related chest pain and had excluded patients on long-term NSAID or high-dose aspirin, or with uncontrolled systemic disease.
Two trials strictly excluded patients with exercise tolerance tests positive for myocardial ischaemia 40 or previous history of cardiovascular disease. 45 
| Conclusions and policy implications
The present systematic review and meta-analysis found no consistent evidence of an association between PPI use and an increased risk of cardiovascular events independent of clopidogrel. The results suggest that initiation of PPI monotherapy should not be avoided on the basis of cardiovascular risk.
